RESUMO
Background: Recombinant human adenovirus type 5 is an oncolytic adenovirus, which can selectively replicate in tumor cells and lyse the tumor cells resulting in dissolution and necrosis of tumor tissues. Aims: To evaluate the efficacy and safety of endoscopic injection of recombinant human adenovirus type 5 in the treatment of advanced esophageal cancer. Methods: A total of 87 patients with advanced esophageal cancer from January 2012 to October 2017 at Qingdao Municipal Hospital were enrolled. According to the treatment performed, patients were divided into recombinant human adenovirus type 5 group (group A), radiation and chemotherapy group (group B) and recombinant human adenovirus type 5 combined with radiation and chemotherapy group (group C). The clinical efficacy, survival rate and adverse reaction rate were compared among the three groups. Results: No significant differences in clinicopathological features were found among the three group (P>0.05). The effective rate, 1-year survival rate, 2-year survival rate, median overall survival, median progression-free survival in groups C were significantly higher than those in group A and group B (P0.05). Adverse reaction rate in group A was significantly decreased than that in group B and group C (P0.05). Conclusions: The therapeutic effect of endoscopic injection of recombinant human adenovirus type 5 combined with radiation and chemotherapy for treatment of advanced esophageal cancer is remarkable, and is an important novel way for the treatment of advanced esophageal cancer, which does not increase obviously the incidence of adverse reactions.